Shanghai InnoStar Bio-tech Co

Shanghai InnoStar Bio-tech Co Rule of 40

The Rule of 40 of Shanghai InnoStar Bio-tech Co (688710.SS) as of Oct 17, 2026 is -26.12 %. In the previous year, Rule of 40 was 26.86 % — a change of -197.24% (lower).

Rule of 40

-26.12 %

YoY

-197.24%

Last updated:

Rule of 40 of Shanghai InnoStar Bio-tech Co is 2025 -26.12 % . Rule of 40 of Shanghai InnoStar Bio-tech Co was 2024 26.86 % . It decreases by -197.24% lower compared to the previous year.

The Shanghai InnoStar Bio-tech Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2022
67.10 CNY
Jan 1, 2023
42.81 CNY
Jan 1, 2024
26.86 CNY
Jan 1, 2025
-26.12 CNY
The Shanghai InnoStar Bio-tech Co Rule of 40 history
YEARRule of 40YoY
-26.12 %-197.24%
26.86 %-37.27%
42.81 %-36.19%
67.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai InnoStar Bio-tech Co Stock analysis

What does Shanghai InnoStar Bio-tech Co do? Shanghai InnoStar Bio-tech Co Ltd is a company based in Shanghai, China, operating within the Life Sciences Tools & Services sector of the Health Care industry. The company has 1,085 employees and completed its initial public offering (IPO) on September 3, 2024. It provides biopharmaceutical non-clinical research services, focusing on early drug development evaluation, non-clinical research, and clinical testing and translational research. The early drug development evaluation involves creating multiple early toxicity rapid prediction and screening models. Non-clinical research encompasses safety evaluation, pharmacokinetic research, and pharmacodynamic research. Clinical testing and translational research offers analytical methods and data support for clinical pharmacokinetics, efficacy, and safety studies related to innovative drug projects. The company's headquarters are located in Shanghai, and it maintains a website at www.innostar.cn. Its stock is listed under the ticker 688710.SS with ISIN CNE1000078J7. Shanghai InnoStar Bio-tech Co Ltd serves the biopharmaceutical sector by supporting the development and evaluation of new drugs through specialized research services. Shanghai InnoStar Bio-tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai InnoStar Bio-tech Co stock

Rule of 40 of Shanghai InnoStar Bio-tech Co is -26.12 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Shanghai InnoStar Bio-tech Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Shanghai InnoStar Bio-tech Co

All Key Metrics — Shanghai InnoStar Bio-tech Co